Greg Mattingly, MD

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

Dr Andrew Cutler and Dr Greg Mattingly review current understanding of anhedonia. They discuss how clinicians can better evaluate it by effectively and candidly communicating with patients about anhedonia.

The expert psychiatrists discuss when to evaluate treatment efficacy and the impact of patients’ quality of life and function in such evaluations.

Dr Andrew Cutler and Dr Greg Mattingly talk about patient profiles they consider for treatment with dextromethorphan-bupropion.

The expert psychiatrists share their clinical experience with dextromethorphan-bupropion.

Dr Greg Mattingly reviews the results of GEMINI and ASCEND trials, which led to approval of dextromethorphan-bupropion.

Dr Greg Mattingly explains the mechanism of action of dextromethorphan-bupropion, a new agent to treat Major Depressive Disorder.

Dr Andrew Cutler and Dr Greg Mattingly discuss newer mechanisms of action to treat patients with Major Depressive Disorder, in particular those with glutamatergic agents.

Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.

David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.

Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.

Greg Mattingly, MD, and David W. Goodman, MD, discuss the recent approval of viloxazine in children and its clinical profile in the pediatric and adult populations in ADHD.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.

Drs Birgit H. Amann, David W. Goodman, and Greg Mattingly discuss signs and symptoms that may prompt testing for adult ADHD and share their considerations for approaching diagnosis.

Experts in the management of ADHD comment on unmet needs in disease management in the areas of diagnosis, treatment, and coverage of symptoms.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; David W. Goodman, MD; Greg Mattingly, MD; and Theresa R. Cerulli, MD, share insight on the impact of ADHD on quality of life in adult patients.

Drs David W. Goodman, Rakesh Jain, Greg Mattingly, and Theresa R. Cerulli, discuss continuation of ADHD from childhood as well as data on remission of ADHD in adulthood.

David W. Goodman, MD; Greg Mattingly, MD; and Birgit H. Amann, MD, provide an overview of ADHD, including its pathophysiology as well as its prevalence in the pediatric and adult populations.